ArticleThe Journal of the Egyptian Public Health Association2026
Global and China burden of maternal sepsis and infections: a systematic global burden of disease 2021 analysis with projections to 2036.
Article in The Journal of the Egyptian Public Health Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMaternal sepsis and maternal infections (MSMIs) pose significant risks to maternal, fetal, and neonatal health. This study examines the burden trends of MSMIs in China from 1990 to 2021, comparing them with global patterns.
methodsThe burden of MSMIs in China and worldwide was evaluated using data from the Global Burden of Disease (GBD) spanning 1990-2021. Temporal trends were assessed through Joinpoint regression, calculating average annual percentage changes (AAPC) with 95% confidence intervals. Future burden projections up to 2036 were estimated using ARIMA modeling. Cross-regional comparisons were conducted to identify variations in disease impact.
resultsBetween 1990 and 2021, China exhibited distinct trends in the burden of MSMIs compared to global patterns. The country's age-standardized incidence rate (ASIR) declined from 29.62 to 23.95 per 100,000, reflecting an annual reduction of -0.73%, in contrast to a global increase to 37.40. Mortality indicators showed significant declines, with China's age-standardized mortality rate (ASMR) dropping by 77.7% to 4.04 (-5.10% per year), compared to a 56.9% global reduction. Disease burden indicators demonstrated accelerated improvements, as China's age-standardized disability-adjusted life years rate (ASDR) fell by 78.3% to 93.73 (-5.31% per year), exceeding the global reduction of 53.1%. Prevalence patterns showed a contraction in China's age-standardized prevalence rate (ASPR) to 390.24 (-0.47% per year), whereas international prevalence rose to 513.68. Age-stratified analysis revealed inverse relationships: ASIR declined progressively with aging, while mortality and disability indicators intensified in older populations, differing from the bimodal prevalence distribution that peaked in middle age.
conclusionFrom 1990 to 2021, China experienced a significant decline in the MSMIs burden, diverging from rising global trends. Projections suggest this divergence will persist, with China's burden continuing to decrease by 2036, while global rates increase. Urgent targeted interventions are needed for high-risk regions and populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.